In an interview with CURE, Dr. Susana Campos, clinical director of the Division of Gynecologic Oncology and assistant professor of medicine at Harvard Medical School, discussed re ...

A novel immunotherapy combination is proving to be both safe and manageable for patients with prostate cancer, according to updated Phase 1 trial data presented at the 2026 ASCO Genitourinary Cancers ...

Cancer treatment has changed dramatically over the past decade. What was once dominated by extensive surgeries followed by aggressive chemotherapy and radiation has now evolved into a more balanced, ...

Dispatch Bio has unveiled with $216 million and the lofty goal of creating a universal treatment for solid tumors using a new immunotherapy approach. The biotech was formed around the concept of ...

After getting engaged, the only words journalist Mrinali Dhembla expected to hear were “I do.” Instead, she was told, “You have cancer.” “When I first heard the words, ‘You have cancer,’ I was ...

The combination of belzutifan plus lenvatinib significantly improved outcomes for patients with clear cell renal cell carcinoma who progressed following immunotherapy compared with cabozantinib ...

Aug. 4 (UPI) --Findings from a study in mice suggest that using a common artificial sweetener, sucralose, could hamper certain immunotherapy treatments in cancer patients. However, for folks reluctant ...

February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and ...

Trilaciclib protects bone marrow before SCLC chemotherapy, sharply reducing neutropenia, anemia, and thrombocytopenia, improving fatigue and keeping treatment on schedule without weakening tumor kill.